$0.15
6.88% yesterday
Nasdaq, Sep 27, 10:18 pm CET
ISIN
US8902604094
Symbol
TNXP
Sector
Industry

Tonix Pharmaceuticals Holding Corp. Stock price

$0.15
-0.22 59.81% 1M
-10.31 98.60% 6M
-12.75 98.87% YTD
-23.45 99.38% 1Y
-3,944.81 100.00% 3Y
-26,406.25 100.00% 5Y
-44,479,999.85 100.00% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
+0.01 6.88%
ISIN
US8902604094
Symbol
TNXP
Sector
Industry

Key metrics

Market capitalization $18.75m
Enterprise Value $23.85m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.91
P/S ratio (TTM) P/S ratio 1.50
P/B ratio (TTM) P/B ratio 0.03
Revenue (TTM) Revenue $12.46m
EBIT (operating result TTM) EBIT $-95.19m
Free Cash Flow (TTM) Free Cash Flow $-75.63m
Cash position $4.16m
EPS (TTM) EPS $-22.15
P/E forward negative
P/S forward 1.52
EV/Sales forward 1.93
Short interest 1.52%
Show more

Is Tonix Pharmaceuticals Holding Corp. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Tonix Pharmaceuticals Holding Corp. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Tonix Pharmaceuticals Holding Corp. forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Tonix Pharmaceuticals Holding Corp. forecast:

Buy
100%

Financial data from Tonix Pharmaceuticals Holding Corp.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
12 12
-
100%
- Direct Costs 15 15
409% 409%
118%
-2.19 -2.19
24% 24%
-18%
- Selling and Administrative Expenses 27 27
14% 14%
220%
- Research and Development Expense 61 61
36% 36%
487%
-90 -90
26% 26%
-725%
- Depreciation and Amortization 4.88 4.88
69% 69%
39%
EBIT (Operating Income) EBIT -95 -95
24% 24%
-764%
Net Profit -149 -149
22% 22%
-1,196%

In millions USD.

Don't miss a Thing! We will send you all news about Tonix Pharmaceuticals Holding Corp. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tonix Pharmaceuticals Holding Corp. Stock News

Neutral
GlobeNewsWire
about 13 hours ago
New patent expected to provide market exclusivity into 2036 Zembrace® SymTouch® (sumatriptan succinate injection) 10mg is indicated for the acute treatment of migraine in adults CHATHAM, N.J., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of developm...
Neutral
GlobeNewsWire
9 days ago
New patent expected to expire in 2030 Tosymra® (sumatriptan nasal spray) 10mg is indicated and marketed for the acute treatment of migraine in adults CHATHAM, N.J., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announ...
Neutral
Accesswire
10 days ago
This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work to ensure that any and all information contained within is true and accurate as of the date hereof to the best of their knowledge and research.
More Tonix Pharmaceuticals Holding Corp. News

Company Profile

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecules and biologics to treat psychiatric, pain and addiction conditions, to improve biodefense through potential medical counter-measures, to treat transplant rejection and to treat gastric and pancreatic cancers. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and Tonmya. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in New York, NY.

Head office United States
CEO Seth Lederman
Employees 103
Founded 2007
Website www.tonixpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today